newsfilter
← Latest News
Business Wire·

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

Presented updated clinical results across oncology pipeline, including a 45% overall response rate (ORR) for zelenectide pevedotin monotherapy and a 45% ORR for BT5528 6.5 mg/m2 every two weeks monotherapy, both in